金戈受仿制药围剿、创新难做、原材料成本上涨、集采冲击下,白云山在合规与治理问题频发之年,2024年四季度单季亏损3.24亿元。 财报数据显示,白云山2024年实现营业收入749.93亿元,同比下降0.69%;净利润28.35亿元,同比下降30.09%。与此同时,白云山核心业务全面承压:大南药、大健康板块营收双降超10%,毛利率持续缩水;“明星单品”金戈库存同比增加49.78%,销量却下滑...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.